Fifth Third Bancorp’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $27.3K | Hold |
2,500
| – | – | ﹤0.01% | 3414 |
|
|
2025
Q4 | $32.3K | Hold |
2,500
| – | – | ﹤0.01% | 1668 |
|
|
2025
Q3 | $32.3K | Hold |
2,500
| – | – | ﹤0.01% | 1700 |
|
|
2025
Q2 | $44.5K | Hold |
2,500
| – | – | ﹤0.01% | 1458 |
|
|
2025
Q1 | $44.5K | Hold |
2,500
| – | – | ﹤0.01% | 1464 |
|
|
2024
Q4 | $74.5K | Hold |
2,500
| – | – | ﹤0.01% | 1242 |
|
|
2024
Q3 | $39.1K | Hold |
2,500
| – | – | ﹤0.01% | 1525 |
|
|
2024
Q2 | $42.8K | Buy |
+2,500
| New | +$44K | ﹤0.01% | 1431 |
|
|
2024
Q1 | – | Sell |
-1,000
| Closed | -$14.9K | – | 2499 |
|
|
2023
Q4 | $14.9K | Sell |
1,000
-254
| -20% | -$3.4K | ﹤0.01% | 1857 |
|
|
2023
Q3 | $20.3K | Sell |
1,254
-750
| -37% | -$21.6K | ﹤0.01% | 1736 |
|
|
2023
Q2 | $83.2K | Buy |
2,004
+1,000
| +100% | +$62.1K | ﹤0.01% | 1204 |
|
|
2023
Q1 | $60.4K | Sell |
1,004
-2,231
| -69% | -$178K | ﹤0.01% | 1369 |
|
|
2022
Q4 | $237K | Buy |
3,235
+896
| +38% | +$67.4K | ﹤0.01% | 893 |
|
|
2022
Q3 | $178K | Buy |
2,339
+1,293
| +124% | +$101K | ﹤0.01% | 968 |
|
|
2022
Q2 | $73K | Hold |
1,046
| – | – | ﹤0.01% | 1231 |
|
|
2022
Q1 | $87K | Buy |
1,046
+8
| +0.8% | +$589 | ﹤0.01% | 1238 |
|
|
2021
Q4 | $78K | Buy |
1,038
+38
| +4% | +$3.81K | ﹤0.01% | 1324 |
|
|
2021
Q3 | $116K | Sell |
1,000
-16
| -2% | -$2.42K | ﹤0.01% | 1127 |
|
|
2021
Q2 | $225K | Buy |
1,016
+16
| +2% | +$3.11K | ﹤0.01% | 942 |
|
|
2021
Q1 | $132K | Sell |
1,000
-2,921
| -74% | -$462K | ﹤0.01% | 1072 |
|
|
2020
Q4 | $678K | Buy |
3,921
+1,270
| +48% | +$174K | ﹤0.01% | 621 |
|
|
2020
Q3 | $295K | Buy |
2,651
+270
| +11% | +$21.6K | ﹤0.01% | 757 |
|
|
2020
Q2 | $141K | Buy |
2,381
+1,218
| +105% | +$80.1K | ﹤0.01% | 984 |
|
|
2020
Q1 | $78K | Buy |
1,163
+158
| +16% | +$12.5K | ﹤0.01% | 1132 |
|
|
2019
Q4 | $85K | Buy |
1,005
+146
| +17% | +$11.8K | ﹤0.01% | 1215 |
|
|
2019
Q3 | $64K | Sell |
859
-913
| -52% | -$73K | ﹤0.01% | 1277 |
|
|
2019
Q2 | $112K | Buy |
1,772
+318
| +22% | +$16.1K | ﹤0.01% | 1095 |
|
|
2019
Q1 | $70K | Buy |
1,454
+578
| +66% | +$27.8K | ﹤0.01% | 1170 |
|
|
2018
Q4 | $29K | Buy |
876
+13
| +2% | +$475 | ﹤0.01% | 1415 |
|
|
2018
Q3 | $45K | Buy |
863
+64
| +8% | +$2.55K | ﹤0.01% | 1351 |
|
|
2018
Q2 | $25K | Buy |
+799
| New | +$22.2K | ﹤0.01% | 1581 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Fifth Third Bancorp's NVCR Position: Q1 2026 in Review
Fifth Third Bancorp held its NovoCure (NVCR) position steady in Q1 2026 at 2,500 shares worth $27.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3414.
Fifth Third Bancorp first reported a position in NVCR in Q2 2018 and has held it in 31 quarters since. The position peaked at $678K in Q4 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Fifth Third Bancorp held 2,500 shares of NovoCure worth $27.3K as of Q1 2026.
- Fifth Third Bancorp left its NovoCure share count unchanged in Q1 2026.
- NovoCure made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #3414 holding.
- Fifth Third Bancorp first reported a position in NovoCure in Q2 2018 and has held it in 31 quarters since.
- Fifth Third Bancorp's NovoCure position peaked at $678K in Q4 2020.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.